| Symbol | ALGS |
|---|---|
| Name | ALIGOS THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | ONE CORPORATE DR.,2ND FLOOR, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 800 - 466-6059 |
| Fax | — |
| — | |
| Website | https://www.aligos.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The companys pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others. Additional info from NASDAQ: |
(99% Neutral) ALIGOS THERAPEUTICS, INC. (ALGS) Announces Business Combination
Read moreAligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Read more(85% Positive) ALIGOS THERAPEUTICS, INC. (ALGS) Announces Enrollment Update for criteria Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreAligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
Read moreCalhoun Lesley Ann 🟢 acquired 37.5K shares (1 derivative) of Aligos Therapeutics, Inc. (ALGS) at $7.03 Transaction Date: Mar 09, 2026 | Filing ID: 000093
Read moreBLATT LAWRENCE 🟢 acquired 105.8K shares (1 derivative) of Aligos Therapeutics, Inc. (ALGS) at $7.03 Transaction Date: Mar 09, 2026 | Filing ID: 000092
Read moreAligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
Read moreNew Form S-8 - Aligos Therapeutics, Inc. <b>Filed:</b> 2026-03-05 <b>AccNo:</b> 0001193125-26-092647 <b>Size:</b> 208 KB
Read moreAligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
Read moreNew Form 3 - Aligos Therapeutics, Inc. <b>Filed:</b> 2026-02-19 <b>AccNo:</b> 0001610717-26-000055 <b>Size:</b> 15 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06963710 | A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovi… | Phase2 | Chronic Hepatitis B Infection | Recruiting | 2025-07-15 | 2028-08-01 | ClinicalTrials.gov |
| NCT06959888 | A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability … | Phase1 | Healthy Volunteer Study | Completed | 2025-03-25 | 2025-05-16 | ClinicalTrials.gov |
| NCT06698549 | A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558… | Phase1 | COVID 19 | Completed | 2025-02-01 | 2025-07-21 | ClinicalTrials.gov |
| NCT06672900 | A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokine… | Phase1 | Healthy Volunteer | Active_Not_Recruiting | 2025-01-09 | 2025-07-07 | ClinicalTrials.gov |
| NCT06342947 | ALG-055009 in Non-cirrhotic Adults With MASH (HERALD) | Phase2 | NASH | Completed | 2024-04-01 | 2024-09-09 | ClinicalTrials.gov |
| NCT06191991 | A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055… | Phase1 | Healthy Volunteers | Completed | 2023-11-03 | 2023-12-04 | ClinicalTrials.gov |
| NCT05840952 | A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the… | Phase1 | COVID-19 | Completed | 2023-07-04 | 2024-04-29 | ClinicalTrials.gov |
| NCT05561530 | A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and P… | Phase1 | Chronic Hepatitis B | Terminated | 2022-10-07 | 2023-06-15 | ClinicalTrials.gov |
| NCT05090111 | A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia | Phase1 | NASH - Nonalcoholic Steatohepatitis | Completed | 2021-12-01 | 2023-06-16 | ClinicalTrials.gov |
| NCT05001022 | A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics a… | Phase1 | Chronic Hepatitis B | Terminated | 2021-09-25 | 2022-07-18 | ClinicalTrials.gov |
| NCT04536337 | A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics a… | Phase1 | Chronic Hepatitis B | Completed | 2020-10-22 | 2025-06-16 | ClinicalTrials.gov |